Related Experiment Video
Updated: Aug 5, 2026
09:07
Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
Published on: June 11, 2020
ICAM-1 antisense oligodeoxynucleotide improves islet allograft survival and function
S M Katz1, F Bennett, K Stecker
1Department of Surgery, The University of Texas Medical School at Houston, 77030, USA. stephen.katz@uth.tme.edu
Cell Transplantation
|February 24, 2001
Summary
Blocking intercellular adhesion molecule-1 (ICAM-1) and leukocyte function antigen-1 (LFA-1) significantly prolongs pancreatic islet allograft survival and improves early function. Dual blockade therapy proved most effective in extending graft survival and enhancing islet function.
Area of Science:
- Immunology
- Transplantation Biology
- Cellular and Molecular Medicine
Background:
- Intercellular adhesion molecule-1 (ICAM-1) and leukocyte function antigen-1 (LFA-1) play critical roles in immune responses following pancreatic islet transplantation.
- Their expression can influence both non-specific and alloantigen-specific phases of islet graft rejection.
Purpose of the Study:
- To investigate the therapeutic potential of blocking the ICAM-1/LFA-1 pathway on pancreatic islet allograft survival and function.
- To compare the efficacy of single versus dual blockade strategies.
Main Methods:
- Pancreatic islets from C57BL/10 mice were transplanted into C3H mice via renal subcapsular space (KC) or portal vein (PV) injection.
- Recipients were treated with ICAM-1 antisense oligodeoxynucleotide (oligo), anti-ICAM-1 monoclonal antibody (mAb), anti-LFA-1 mAb, or combinations thereof.
- Donor pretreatment strategies were also evaluated.
- Graft survival, glucose tolerance tests, and inflammatory markers were assessed.
Main Results:
- Single agent blockade (ICAM-1 oligo, anti-ICAM-1 mAb, or anti-LFA-1 mAb) significantly prolonged KC islet allograft survival compared to controls.
- Dual blockade using ICAM-1 oligo/anti-LFA-1 mAb or anti-ICAM-1 mAb/anti-LFA-1 mAb demonstrated superior efficacy in extending graft survival.
- Combined donor pretreatment and recipient treatment further enhanced graft survival.
- ICAM-1/LFA-1 blockade improved islet function and reduced inflammation.
Conclusions:
- ICAM-1/LFA-1 blockade is a promising strategy for prolonging pancreatic islet allograft survival.
- Dual blockade therapies offer enhanced therapeutic benefits over single agent treatments.
- This approach also improves early graft function and reduces inflammatory processes post-transplantation.
